팝업레이어 알림

팝업레이어 알림이 없습니다.

Start to become a
global biotech company

For the healthy
and happy life of mankind

Our efforts for
a great challenge

about us

A joint research venture founded by Samyoung Unitech Co., Ltd. and Daegu Gyeongbu Institute of Science and Technology for the development of new peptides.

Sylus Co., Ltd., established in April 2019, is a research joint venture by Samyoung Unitech Co., Ltd. and Daegu Gyeongbuk Institute of Science and Technology for the development of new peptides.Starting with the development of anemia treatment drugs, we are focusing on the development of various disease treatments, including neurodegenerative diseases.
Samyoung Unitech, the parent company of Sylus, is a radiopharmaceutical manufacturing company and the first company to receive KGMP certification for radiopharmaceuticals.

go to samtoung unitech home page →

therapeutic focus

  • Degenerative Brain Disease
  • Cell protection
  • Kidney failure

sylus

Take the leap into a global biotech company

Sylus was incorporated in April 2019 and is headquartered in the Jeonbuk Special Economic Zone.
We are developing new peptide drug treatments for a healthy society and striving to become a global biotech company.

  • Sylus is promoting the development of innovative peptide treatments through in-house research in close cooperation with academia and industry.
    Beginning with the development of anemia treatment drugs, Sylus’s new drug development project will continue for the complete treatment of various diseases, including the development of remedies for degenerative neurological diseases using cell protection.

oraganization

  • Dedicated Research Department
  • Research Planning Room

pipeline

  • Degenerative Brain Disease
  • Cell protection
  • Kidney failure

development stage

- Drug Discovery

- IND - Enabling

  • SY-A-1
    Anemia's undisclosed

    SY-A-1

    Development Stage
    : Drug Discovery
    Summary
    : SY-A-1 can treat or alleviate amemia, hematopoiesis and improve the overall hematoqenous functions of the body.
  • SY-D-1
    Degenerative diseases of the nervous system's undisclosed

    SY-D-1

    Development Stage
    : Drug Discovery
    Summary
    : SY-D-1 has excellent bioactivity with respect to cell-protecting activity and does not have side effects on cell proliferation

- Phase 1

- Phase 2

X

founder

Introducing the founder of Sylus.

  • Kyung-il, Jung, CEO
    1992.07 ~ Present : President, Samyoung Unitech Co., Ltd.
    2010.06 ~ Present : President, Atom Export Club
    2010.09 ~ Present : Councilor, Korea Atomic Energy Society (17th~25th)
    2018.01 ~ Present : Member, The Korean Association for Radiation Protection
    2019.04 ~ Present : President, Korean Association for Radiation Application (13th)

news

  • careers

    Sylus strives to successfully develop new drug treatments for a healthy society.
    We value our commitment and to the highest professional standard in the industry and a persistent attitude to problem-solving.

    Inquiry : sylus@sylus.co.kr

    investor

    contact

    Thank you for visiting the Sylus homepage.

    • Headquarters
      Headquarters: #503, 68, Giji-ro, Deokjin-gu, Jeonju-si, Jeollabuk-do, South Korea
      Suji office: A-1401, 767, Sinsu-ro, Suji-gu, Yongin-si, Gyeonggi-do, South Korea
    • laboratory
      #406-B R7 building, 333, Techno jungang-daero, Hyeonpung-eup, Dalseong-gun, Daegu, South Korea
    • e-mailsylus@sylus.co.kr
      tel070.7450.8813